About Vitronectin
Vitronectin (VTN) is a protein
from Homo sapiens identified by UniProt accession
P04004, 478 residues long.
MolForge cross-references it against 0 known binders and
567 disease associations.
Target properties
| Protein name | Vitronectin |
| UniProt accession | P04004 |
| Gene | VTN |
| Organism | Homo sapiens |
| Length | 478 residues |
| Molecular weight | — |
| EC numbers | — |
| Target class | UNCLASSIFIED |
| Subcellular location | — |
| Keywords | — |
Druggability
Target tractability assessment (Open Targets + pocket analysis). No approved drug
| Druggability tier | MEDIUM |
| Druggability score | — |
| Pocket score | — |
| Max clinical phase | — |
Disease associations (567)
Diseases linked to this target (Open Targets).
- neurodegenerative disease · score 0.34
- blood protein measurement · score 0.28
- breast adenocarcinoma · score 0.25
- low density lipoprotein cholesterol measurement · score 0.25
- neuroinflammatory disorder · score 0.23
- lung adenocarcinoma · score 0.21
- heel bone mineral density · score 0.21
- triglyceride measurement · score 0.21
- systolic blood pressure · score 0.19
- apolipoprotein B measurement · score 0.19
3D Structure (1)
Experimental (PDB) and predicted (AlphaFold) structures for this protein.
| Structure | Source | Method | Mean pLDDT | Resolution (Å) |
| AF-P04004-F1 | alphafold | PREDICTED | 67.18 | — |
Amino-acid sequence (478 residues)
MAPLRPLLIL ALLAWVALAD QESCKGRCTE GFNVDKKCQC DELCSYYQSC CTDYTAECKP QVTRGDVFTM PEDEYTVYDD GEEKNNATVH EQVGGPSLTS DLQAQSKGNP EQTPVLKPEE EAPAPEVGAS KPEGIDSRPE TLHPGRPQPP AEEELCSGKP FDAFTDLKNG SLFAFRGQYC YELDEKAVRP GYPKLIRDVW GIEGPIDAAF TRINCQGKTY LFKGSQYWRF EDGVLDPDYP RNISDGFDGI PDNVDAALAL PAHSYSGRER VYFFKGKQYW EYQFQHQPSQ EECEGSSLSA VFEHFAMMQR DSWEDIFELL FWGRTSAGTR QPQFISRDWH GVPGQVDAAM AGRIYISGMA PRPSLAKKQR FRHRNRKGYR SQRGHSRGRN QNSRRPSRAT WLSLFSSEES NLGANNYDDY RMDWLVPATC EPIQSVFFFS GDKYYRVNLR TRRVDTVDPP YPRSIAQYWL GCPAPGHL
Explore Vitronectin with MolForge
Find binders, run structure-based screening, and map this target across
diseases and approved drugs with our AI-powered platform.
Browse all targets